Dear Einstein Community:

After an extensive, nationwide search, I’m pleased to announce that Edward Chu, M.D., M.M.S., will join us as director of our National Cancer Institute-designated Albert Einstein Cancer Center. He also will serve as vice president for cancer medicine at Montefiore Medicine, be appointed professor of medicine and of molecular pharmacology, and will hold the Carol and Roger Einiger Professorship of Cancer Medicine at Einstein. In these roles, Dr. Chu will unite Einstein and Montefiore’s cancer programs into a fully integrated research and clinical enterprise. He will assume these duties on October 1, 2020.

We’re excited to have Dr. Chu bring his unique set of skills to the Bronx and to our community. As deputy director of the University of Pittsburgh Medical Center’s (UPMC) Hillman Cancer Center (HCC), associate director of the University of Pittsburgh Drug Discovery Institute, and chief of the division of hematology-oncology, he has demonstrated his excellence in clinical care, research, and drug development. He also is a committed mentor, dedicated to training the next generation of physician-scientists, who are vital to moving the field of cancer research and treatment forward.

In addition to his current leadership positions, Dr. Chu is co-leader of the HCC Cancer Therapeutics Program and director of the HCC Phase I Program. He is a NIH-funded basic, translational, and clinical investigator and clinical oncologist, with a long history of developing and leading phase I and phase II clinical trials, particularly for colorectal cancer and other gastroenterology cancers. And he has shown great devotion to delivering the best care for all patients, regardless of circumstances.

With his expertise in cancer pharmacology and drug development, he has been active in designing and developing novel agents and treatment approaches. His
research has also focused on the molecular mechanisms underlying drug resistance on the cellular level and he holds a patent on a novel siRNA therapeutic molecule. Additionally, he has studied Chinese herbal medicine and its integration with standard care with the goal of improving outcomes and reducing the toxic side effects of chemotherapy.

Dr. Chu is a native New Englander, having grown up in New Haven, CT and Providence, RI. He received his undergraduate, masters, and medical degrees from the Brown University Program in Liberal Medical Education and stayed on at Brown University for his internal medicine residency, training at Roger Williams General Hospital. He completed his medical oncology fellowship at the NCI in Bethesda, MD, where he was subsequently appointed a member of the senior staff and then a tenured senior clinical investigator in the NCI Medicine Branch and NCI-Navy Medical Oncology Branch.

In 1996, he was recruited to the Yale University School of Medicine, where he first served as director of the VA Connecticut Cancer Center and co-leader of the Yale Cancer Center (YCC) Developmental Therapeutics Research Program. In 2004, he was appointed chief of medical oncology and YCC associate director of clinical and translational research and was subsequently named in 2007 to be YCC’s deputy director. In 2010, he was recruited to the University of Pittsburgh.

I hope you’ll join me in welcoming Dr. Chu to Einstein and Montefiore. And I invite you to read our press release, which further details why he is the ideal candidate to take the cancer enterprise at Einstein and Montefiore into the future.

I’d also like you to join me in thanking I. David Goldman, M.D., for his decades of exceptional leadership at the helm of our AECC.

Sincerely,

Gordon F. Tomaselli, M.D.
The Marilyn and Stanley M. Katz Dean
Albert Einstein College of Medicine
Executive Vice President and Chief Academic Officer